ArticleFrontiers in oncology2026
Impact of stereotactic radiosurgery dose on local control and radiation necrosis in metastatic brain lesions: a comparative study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate and compare the efficacy of stereotactic radiosurgery (SRS) prescription doses on local control (LC) rates of brain metastases and radiation necrosis (RN) risk. Methods: A retrospective review was conducted on patients treated between January 2018 and December 2023 at a single institution with single-fraction SRS at doses of 20 Gy, 22 Gy, or 24 Gy. The effects of radiation dose on LC and RN were evaluated using univariate analysis, then with multivariate logistic regression adjusting for gross tumor volume (GTV) and history of post-SRS whole-brain radiation therapy (WBRT). Results: The study included 332 brain metastases from 159 patients. 127 lesions were treated with 20 Gy (38.3%), 183 with 22 Gy (55.1%), and 22 with 24 Gy (6.6%). Median follow-up was 14 months. One-year LC rates were 96.3% for 22 Gy versus 90.1% for 20 Gy (p = 0.032). On multivariable logistic regression, 22 Gy was still associated with higher odds of 1-year LC compared with 20 Gy (adjusted OR 3.04, 95% CI 1.22-7.59; p = 0.017). Both SRS dose and GTV were independent predictors of RN (dose adjusted OR 2.05, p = 0.016; GTV adjusted OR 1.40 per doubling volume, p < 0.001). Overall survival did not differ significantly by dose (p = 0.63). Conclusion: In this retrospective cohort, SRS at 22 Gy was associated with higher local control than 20 Gy. Larger GTV volumes were independently associated with a higher risk of RN. WBRT post SRS was not an independent risk factor for RN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.